secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncology Institute, Inc. (TOI)
CIK:        0001799191
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001079973-26-000611
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TOI Q1 revenue up 41% to $147.4M, net loss narrows to $2.5M
-----------------------------------------------------------

- Revenue $147.4M (+41% YoY); net loss $2.5M vs $19.6M loss prior year.
- Adjusted EBITDA loss $2.4M improved from $5.1M loss; EPS $(0.02) vs $(0.21).
- Specialty Pharmacy revenue up 78% YoY; record Part D fills.
- Medicare Advantage lives to reach 200,000 in Florida effective July 1, 2026.
- CMS Enhancing Oncology Model saved ~$2M in period 3; full-year guidance reaffirmed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799191/000107997326000611/0001079973-26-000611-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799191/000107997326000611/toi_8k.htm
  HTML page:      https://secwatch.observer/filing/0001079973-26-000611

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer